Can-Fite BioPharma Ltd. (CANF:NYSEMKT) closed at $1.89 on October 20, 2026, unchanged on the day. The stock trades 84.8% below its 52-week high of $12.40 and 8.0% above its 52-week low of $1.75. Over the past year, it lost 81.1%. Can-Fite BioPharma Ltd. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 20, 2025, CANF closed higher on 94 days (37%). Its best day was July 1, 2026 (+55.89%) and its worst was September 2, 2026 (-28.27%). The stock moved 10% or more in a single session 17 times. It opened at least 5% above the previous day's high 7 times.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and ophthalmic diseases, as well as sexual dysfunction. It offers CF101, which has completed Phase II/III clinical trials for the treatment of psoriasis; completed Phase II clinical trials for the treatment of rheumatoid arthritis; completed Phase I clinical study for the treatment of osteoarthritis; and completed Phase I study for the treatment of uveitis, as well as is in Phase II clinical trials for the treatment of glaucoma or related syndromes of ocular hypertension. The company also develops CF102 that conducts a Phase II study for treating hepatocellular carcinoma and hepatitis C virus; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.
Find more stocks like CANF with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.